Get the Stockscreener App
7.78
2.91%
0.22
Pre-market:
7.84
0.06
+0.77%
Sellas Life Sciences Group Inc stock is traded at $7.78, with a volume of 10.65M.
It is up +2.91% in the last 24 hours and up +62.76% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$7.56
Open:
$7.67
24h Volume:
10.65M
Relative Volume:
1.44
Market Cap:
$1.45B
Revenue:
-
Net Income/Loss:
$-26.86M
P/E Ratio:
-31.65
EPS:
-0.2458
Net Cash Flow:
$-28.39M
1W Performance:
+9.89%
1M Performance:
+62.76%
6M Performance:
+408.50%
1Y Performance:
+342.05%
1-Day Range:
$7.3512
$8.27
1-Week Range:
$6.85
$9.0999
52-Week Range:
$1.39
$9.0999
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
7.78 | 1.41B | 0 | -26.86M | -28.39M | -0.2458 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SLS Stock Rallies After Hours As CEO Teases Leukemia Study Data Any Day Now - Stocktwits
SLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readout - MSN
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
Why did ARM, SLS, EBAY stocks surge to 52-week highs? - MSN
SLS stock tanks hard: Retail traders blame warrant holders, 'flippers' cashing out before AML catalyst - MSN
SLS stock pops big after hours on imminent leukemia trial data readout optimism - MSN
SLS stock rallies after hours as CEO teases leukemia study data any day now - MSN
NBIS, CSCO, SLS stocks hit 52-week highs today: What's behind the surge? - MSN
SLS stock hits over 4-year high: CEO eyes FDA talks, ‘whole gamut’ of cancer uses for GPS - MSN
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS) - Seeking Alpha
Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop - simplywall.st
SLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomes - MSN
SELLAS Life Sciences Group Down Nearly 19%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk - Moomoo
SLS Stock Pulls Back As Cash Pile Extends Biotech Runway - StocksToTrade
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs? - Stocktwits
SLS: Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials - TradingView
SLS Stock Jumps As Cash Pile Grows And Trial Catalysts Near - StocksToTrade
SLS Stock Jumps As SELLAS Boosts Cash And Near-Term Catalysts - timothysykes.com
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move? - Benzinga
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus - TechStock²
SLS: Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts - TradingView
SLS: GPS and SLS-009 advance in AML, with pivotal data and biomarker-driven expansion expected soon - TradingView
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earnings - MSN
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story - simplywall.st
SLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readout - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SELLAS Life Sciences Group, Inc.Common Stock (NQ: SLS - FinancialContent
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade - MSN
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SLS stock surges into conference season as investors hunt for AML readout hints - MSN
SELLAS Nears Key AML Data As Dual Trials Shape High-Risk Outlook - simplywall.st
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):